Which is the strongest anti-cancer drug sales in 2022? TOP10 varieties announced! Qilu, Hengrui, Stone Medicine... Leading domestic pharmaceutical companies

In the Chinese drug market, the sales of anti-tumor drugs have been showing a steady growth trend
in recent years.
In 2019, the number of new cancer onset in China reached 4.
400 million, accounting for about a quarter of the global cancer incidence
.
Affected by the aging of the population, environmental pollution and unhealthy lifestyles, the number of new cancer patients in China is expected to further increase to 4.
986 million by 2024, indicating the growing
demand for anti-tumor drugs.
Sales of anti-tumor drugs in hospitals

Screenshot source: Yaorongyun National Hospital Sales Database According to Yaorongyun statistics, the total market sales of anti-tumor drugs in 2021 exceeded 88.
5 billion yuan, an increase of 13% year-on-year, and it is also growing
steadily in 2022.
From the perspective of enterprises, there are 4 multinational enterprises in the TOP10 pharmaceutical companies, namely Roche, AstraZeneca, Pfizer and Novartis Pharmaceutical, and there are 6 local pharmaceutical companies, namely Qilu Pharmaceutical, Jiangsu Hengrui, CSPC Ouyi, Chia Tai Tianqing, Jiangsu Haosen and Cinda Biologics
.
See the table below
for details.
2022 H1 anti-tumor drug hospital market manufacturers TOP10

Data source: Yaorongyun National Hospital Sales Database combined with the recently updated Yaorongyun National Hospital Sales 2022 Q2 data, in 2022 H1 has 10 anti-tumor drugs sales exceeded 1 billion yuan, reflecting the clinical value and market potential
of these drugs.
Roche's "troika" - bevacizumab injection, trastuzumab for injection and rituximab are all on the list, and these 3 drugs are also monoclonal antibodies
with more biosimilars.
Compared with H1 in 2021, pittozumab injection and anlotinib hydrochloride capsules are newly listed in the top 10 in hospital sales, ranking 8th and 10th
.
In 2022, H1 anti-tumor drugs are sold in the hospital TOP10

Data source: Yaorong Cloud National Hospital Sales Database

01

Bevacizumab injection

The first batch of domestic time: March 2010

2022 H1 sales: 3.
238 billion yuan

Approved enterprises: Roche, Fuhong Henlius, Dongyao Pharmaceutical, Beida Pharmaceutical, Biotech Biologics, Suzhou Shengdia Biologicals, Dongboan Biologics, Xinda Biologics, Qilu Pharmaceuticals

In December 2019, Qilu was approved to produce bevacizumab injection (trade name: Anda), which is the first domestic bevacizumab biosimilar
.
With the approval of a number of biosimilars, the market of the original research Roche has been repeatedly squeezed, and Qilu has become the leader in the drug market
.
In the H1 hospital market in 2022, Qilu Pharmaceutical has more than half of the market share, surpassing the original research Roche (market share of 24%) to become the main force in
the market.

02

Trastuzumab for injection

The first batch of domestic time: December 2002

2022 H1 sales: 2.
739 billion yuan

Approved enterprises: Roche, Rongchang Biological, Fuhong Henlius

Trastuzumazim is researched from Roche and is one of
its blockbuster oncology "troika".
In 2017, trastuzumab entered the medical insurance directory with a 65% reduction, and the price of each bottle was reduced from 21613 yuan to 7600 yuan
.
At present, there are other Anke Biological, Haizheng Pharmaceutical trastuzumab biosimilars have also been reported on the market, Sansheng Guojian's HER2 antibody is not similar due to glycosylation, according to the 2 new drugs declared, the generic name is initalumab
.
Trastuzumab of Zhejiang Medicine, Jiahe Biologics, Qilu Pharmaceutical, etc.
is in Phase III clinical development
.

03

Oxitinib mesylate tablets

The first batch of domestic time: March 2017

2022 H1 sales: 22.
58 billion yuan

Approved enterprise: AstraZeneca

Oxitinib mesylate tablets (hereinafter referred to as ositinib) are the world's first approved third-generation EGFR-TKI targeted therapy drug with first-line therapeutic indications
.
At present, only the original research in China has been approved to list this variety, in addition, Jiangsu Wanbang Biochemical Pharmaceutical has submitted a 4 types of imitation listing application in May 2021, which is still under review and approval, and if it can be successfully approved this year, it may become a new sales growth point for
the company.

04

Paclitaxel for injection (albumin-conjugated)

The first batch of domestic time: March 2008

2022 H1 sales: 19.
65 billion yuan

Approved enterprises: CSPC Ouyi, Jiangsu Hengrui, Celgene Corporation, Qilu, Hainan Kelun, Zhejiang Haizheng Pharmaceutical

Developed by Singki, Paclitaxel for Injection (albumin-conjugated) and has been approved for marketing in more than 30 countries around the world, was approved for import in 2008 by China for the treatment of metastatic breast cancer that failed with combination chemotherapy or breast cancer that recurred within 6 months after adjuvant chemotherapy
.

05

Goserelin acetate sustained-release implant

The first batch of domestic time: March 1996

2022 H1 sales: 17.
08 billion yuan

Approved enterprise: AstraZeneca

AstraZeneca's Goserelin acetate sustained-release implant is a first-line drug for the treatment of prostate cancer, which has been listed in China for more than 20 years and is still an exclusive variety on the market, because as a sustained-release implantant of polypeptide hormones, it is also necessary to configure a pre-filled syringe for implantation, which has high
requirements for preparation technology, equipment, and drug delivery devices.
In August this year, Shandong Luye Pharmaceutical submitted a Class 2.
2 listing application for Goserelin acetate extended-release microspheres (LY01005) for injection, which is under
review and approval.

06

Pemetrexed disodium for injection

Domestic first batch of time: 2005 2022 H1 sales: 1.
611 billion yuan approved enterprises: Sichuan Huiyu Pharmaceutical, Jiangsu Aosaikang, Simcere Pharmaceutical, Yangzijiang, Lilly, Qilu Pharmaceutical, Suzhou Erye Pharmaceutical and other more than 20 domestic and foreign pharmaceutical companies for injection Pemetrexed disodium original research from the United States Lilly, in many areas of anti-tumor treatment have been used, because of the wide range of use, the use of large amounts, there
are antibiotics in the field of tumors 。 Since 2005, after Haosen broke through the technical barriers and obtained the first imitation qualification of pemetrexed disodium sodium, a number of pharmaceutical companies have successively obtained the approval of this variety, and many pharmaceutical companies such as Huiyu Pharmaceutical (the first one to be evaluated), Jiangsu Haosen, Yangzijiang and many other pharmaceutical companies have been evaluated
.
In 2022 H1, the hospital market for injection of pemetrexed disodium is mainly occupied
by Sichuan Huiyu Pharmaceutical (accounting for more than 40%), Lilly, Jiangsu Haosen, Qilu Pharmaceutical and other enterprises.

07

Rituximab injection

The first batch of domestic time: March 2002

2022 H1 sales: 14.
87 billion yuan

Approved enterprises: Roche, Cinda Biologics, Henlius Fuhong

Rituximab is the world's first marketed anti-tumor monoclonal antibody and the first approved biosimilar drug in China
.
Unlike the sharp decline in global sales of rituximab, the domestic market for rituximab is still growing steadily, with hospital sales of 3.
1 billion yuan in 2021, an increase of 18%
year-on-year.
At present, the domestic Chia Tai Tianqing rituximab biosimilar has been in the market review, and Shandong New Era Pharmaceutical, Shanghai Institute of Biological Products, Hualan Gene, Nanjing Youke Biological, Xikang (Wuhan) Biological, Zhejiang Haizheng Pharmaceutical and other pharmaceutical companies are in the phase III clinical development stage
.

08

Pittozumab injection

The first batch of domestic time: March 2018

2022 H1 sales: 14.
43 billion yuan

Approved enterprise: Roche

Pittolizumab is a HER2/neu receptor antagonist developed by Genentech Corporation (acquired by Roche) with global sales of $4.
78 billion
in 2021.
At present, no biosimilar drugs in China have been approved for listing, but there are already a number of pharmaceutical companies, among which Fuhong Hanlin, Chia Tai Tianqing and Qilu Pharmaceutical have made the fastest progress and are already in the stage III clinical development
.

09

Doxorubicin hydrochloride liposome injection

The first batch of domestic time: March 2008

2022 H1 sales: 13.
01 billion yuan

Approved enterprises: Changzhou Jinyuan Pharmaceutical, CSPC Ouyi, Shanghai Fudan Zhangjiang Biological

Liposomal drugs are often difficult to develop and are pharmaceutical/clinically
challenging.
Doxorubicin hydrochloride liposome injection is a special injection formed by using ammonium sulfate gradient method to wrap doxorubicin hydrochloride in PEG liposomes, which is a complex injection, and the research and development technology is very difficult and the preparation process is complex
.
At present, a total of 3 generic pharmaceutical companies in China, such as CSPC Pharmaceutical Group, Changzhou Jinyuan Pharmaceutical and Fudan Zhangjiang (Shoufang), have been approved, of which only CSPC Ouyi passed the consistency evaluation
in May 2021.

10

Anlotinib hydrochloride capsules

The first batch of domestic time: March 2018

2022 H1 sales: 11.
9 billion yuan

Approved enterprise: Chia Tai Tianqing

Anlotinib hydrochloride capsule is a class 1 innovative drug independently developed by Chia Tai Tianqing, which was first declared clinical in 2010 and was first approved for marketing
in 2018.
In April this year, the new indication of "Anlotinib" was approved for marketing
.
So far, alotinib has been approved in 4 cancer species, including non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, and medullary thyroid cancer, and this time it has once again won the 5th indication for locally advanced or metastatic differentiated thyroid cancer (RAIR-DTC)
that cannot be operatively resisted by iodine therapy.